A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC · NCT07573176
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–74 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 600
- US sites recruiting
- 34
- Study start
- April 30, 2026
- Record last updated
- October 1, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder ([MDD], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.
Being studied: Seltorexant; Placebo
Conditions: Depressive Disorder, Major
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment and confirmed by the SCID-CT diagnosed with first depressive episode prior to age 55
- Experienced at least one MDD episode prior to their current episode based on clinician-confirmed MDD diagnosis/MDE and documented in source records
- Current episode of MDD must be a minimum of 8 weeks in duration and maximum of 24 months duration
- Must meet one of the following criteria regarding current medication status.
- Can be presenting for a new episode of MDD with no adequate antidepressant treatment started in the current episode; however, must have been treated with an antidepressant medication in a prior episode for a minimum of 6 weeks at a stable dose at or above the minimum therapeutic level.
OR
- Have taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to inadequate response as defined by the Massachusetts general hospital antidepressant treatment response questionnaire (MGH-ATRQ)
- Body Mass Index (BMI) between 18 and 40 kilograms per square meter (kg/m\^2)
- Must be medically stable on the basis of the following performed at screening and double-blind (DB) baseline: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead electrocardiogram (ECG)
Exclusion criteria
- Use of ketamine/esketamine in the current depressive episode (up to 2 doses are allowed prior to screening)
- Has treatment-resistant depression (TRD)
- Has a primary DSM-5 diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia which has been the primary focus of psychiatric treatment within the past 2 years
- Current active DSM-5 diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa, or fibromyalgia
- Has a history or current diagnosis of a psychotic disorder, bipolar disorder, autism spectrum disorder, borderline personality disorder, or somatoform disorders
- Has dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months or a history of suicidal behavior within the past 6 months
- Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months
- Has any significant sleep disorder, including but not limited to untreated/uncontrolled conditions
- Has known allergies, hypersensitivity, intolerance, or any contraindication to seltorexant or its excipients
Recruiting US locations
SanRo Clinical Research Group LLC WCG Clinical Network
Bryant, AR 72022
CI Trials
Bellflower, CA 90706
Behavioral Research Specialists LLC
Glendale, CA 91206
Excell Research Inc
Oceanside, CA 92056
NRC Research Institute
Orange, CA 92868
Cenexel
Riverside, CA 92506
Sunwise Clinical Research
Walnut Creek, CA 94596
UHC Research
Doral, FL 33178
Reliable Clinical Research
Hialeah, FL 33012
Pharmax Research Clinic Inc
Miami, FL 33126
Nuovida Research Center
Miami, FL 33186
IPTB Clinical Research
Tampa, FL 33629
Health Synergy Clinical Research
West Palm Beach, FL 33407
Agile Clinical Research Trials, LLC
Atlanta, GA 30328
Accelerated Clinical Research Group LLC
Snellville, GA 30078
Chicago Research Center
Chicago, IL 60634
Pharmasite Research, Inc.
Baltimore, MD 21208
Adams Clinical Boston
Boston, MA 02116
Adams Clinical Watertown
Watertown, MA 02472
Vector Clinical Trials
Las Vegas, NV 89128
CenExel Marlton NJ
Marlton, NJ 08053
Integrative Clinical Trials LLC
Brooklyn, NY 11229
SPRI Clinical Trials, LLC
Brooklyn, NY 11235
Bioscience Research LLC
Mount Kisco, NY 10549
Fieve Clinical Research Inc
New York, NY 10017
Adams Clinical Harlem
New York, NY 10029
Manhattan Behavioral Medicine
New York, NY 10036
Magnolia Clinical Research LLC
Cary, NC 27511
Patient Priority Clinical Sites LLC
Cincinnati, OH 45215
Conrad Clinical Research
Edmond, OK 73013
Sooner Clinical Research
Oklahoma City, OK 73116
Future Search Trials of Dallas
Dallas, TX 75251
Alpine Research Organization
Clinton, UT 84015
Northwest Clinical Research Center
Bellevue, WA 98007
Study contacts (from the official record)
- Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Similar studies in Arkansas
All mental health studies in Arkansas →- RecruitingPhase 1Overnight stay mentioned
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Leal Therapeutics, Inc
- Location
- Little Rock, AR + 9 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Little Rock, AR + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals
- Location
- Bentonville, AR + 16 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bristol-Myers Squibb
- Location
- Little Rock, AR + 18 other US sites
- Eligibility basics
- Ages 18–65